{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:47:59Z","timestamp":1792666079091,"version":"4.5.0"},"reference-count":135,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Peritoneal metastasis (PM) is a major challenge in advanced gastric cancer (GC) with poor prognosis. Normothermic intraperitoneal and systemic treatment (NIPS) has become a promising therapeutic approach. This consensus aims to provide practical recommendations for NIPS treatment for gastric cancer with peritoneal metastasis (GCPM). The GRADE standards were used to rank evidence, and the Delphi method was employed for expert voting. 30 experts from China, Japan, South Korea, and Singapore participated in the development of this consensus. 28 experts participated in the voting process, which produced 29 statements covering diagnostic approaches, patient selection criteria, treatment regimens, management of intraperitoneal port placement, and conversion surgery considerations, and post-surgical treatment strategies in NIPS therapy. Based on current evidence and expert experience, these statements aim to improve the clinical outcomes of NIPS therapy for GCPM patients.<\/jats:p>","DOI":"10.1007\/s10120-025-01631-9","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T10:41:04Z","timestamp":1752489664000},"page":"731-748","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Asian consensus on normothermic intraperitoneal and systemic treatment for gastric cancer with peritoneal metastasis"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1795-0706","authenticated-orcid":false,"given":"Zhenggang","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joji","family":"Kitayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung-Ho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy Bok-Yan","family":"So","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangdong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiankun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiro","family":"Imano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Ishigami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye Seob","family":"Jee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Han","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Kodera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Mou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Jun","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zekuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongyin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Yonemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Peng","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiren","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Asian Gastric Cancer NIPS Treatment Collaborative Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"1631_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA: A Cancer J Clin"},{"key":"1631_CR2","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ejso.2022.08.023","volume":"49","author":"R Yang","year":"2023","unstructured":"Yang R, Su Y, Ma R, Li Y. Clinical epidemiology of peritoneal metastases in China: the construction of professional peritoneal metastases treatment centers based on the prevalence rate. Eur J Surg Oncol. 2023;49:173\u20138.","journal-title":"Eur J Surg Oncol"},{"key":"1631_CR3","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1046\/j.1365-2168.2000.01360.x","volume":"87","author":"CH Yoo","year":"2000","unstructured":"Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg. 2000;87:236\u201342.","journal-title":"Br J Surg"},{"key":"1631_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-012-0163-4","volume":"16","author":"A Nashimoto","year":"2013","unstructured":"Nashimoto A, Akazawa K, Isobe Y, Miyashiro I, Katai H, Kodera Y, et al. Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer. 2013;16:1\u201327.","journal-title":"Gastric Cancer"},{"key":"1631_CR5","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1016\/j.ejso.2013.07.021","volume":"39","author":"F Coccolini","year":"2013","unstructured":"Coccolini F, Capponi MG, Campanati L, Piazzalunga D, Manfredi R, Colaianni N, et al. Intraperitoneal chemotherapy in advanced gastric cancer. meta-analysis of randomized trials. Eur J Surg Oncol (EJSO). 2013;39:S39-40.","journal-title":"Eur J Surg Oncol (EJSO)"},{"key":"1631_CR6","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1245\/s10434-017-5838-y","volume":"24","author":"N Ikoma","year":"2017","unstructured":"Ikoma N, Chen H-C, Wang X, Blum M, Estrella JS, Fournier K, et al. Patterns of initial recurrence in gastric adenocarcinoma in the era of preoperative therapy. Ann Surg Oncol. 2017;24:2679\u201387.","journal-title":"Ann Surg Oncol"},{"key":"1631_CR7","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/ijc.28373","volume":"134","author":"I Thomassen","year":"2014","unstructured":"Thomassen I, Gestel YR, Ramshorst B, Luyer MD, Bosscha K, Nienhuijs SW, et al. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer. 2014;134:622\u20138.","journal-title":"Int J Cancer"},{"key":"1631_CR8","doi-asserted-by":"publisher","first-page":"570","DOI":"10.3390\/cancers14030570","volume":"14","author":"BJ Sun","year":"2022","unstructured":"Sun BJ, Lee B. Review of regional therapies for gastric cancer with peritoneal metastases. Cancers. 2022;14:570.","journal-title":"Cancers"},{"key":"1631_CR9","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.ejso.2006.03.007","volume":"32","author":"Y Yonemura","year":"2006","unstructured":"Yonemura Y, Bandou E, Sawa T, Yoshimitsu Y, Endou Y, Sasaki T, et al. Neoadjuvant treatment of gastric cancer with peritoneal dissemination. Eur J Surg Oncol (EJSO). 2006;32:661\u20135.","journal-title":"Eur J Surg Oncol (EJSO)"},{"key":"1631_CR10","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","volume":"36","author":"H Ishigami","year":"2018","unstructured":"Ishigami H, Fujiwara Y, Fukushima R, Nashimoto A, Yabusaki H, Imano M, et al. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol. 2018;36:1922\u20139.","journal-title":"J Clin Oncol"},{"key":"1631_CR11","doi-asserted-by":"publisher","first-page":"905922","DOI":"10.3389\/fonc.2022.905922","volume":"12","author":"Z-Y Yang","year":"2022","unstructured":"Yang Z-Y, Yuan F, Lu S, Xu W, Wu J-W, Xi W-Q, et al. Efficacy and safety of conversion therapy by intraperitoneal and intravenous paclitaxel plus oral S-1 in gastric cancer patients with peritoneal metastasis: a prospective phase II study. Front Oncol. 2022;12:905922.","journal-title":"Front Oncol"},{"key":"1631_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s10120-016-0662-9","volume":"20","author":"D Kobayashi","year":"2017","unstructured":"Kobayashi D, Kodera Y. Intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis. Gastric Cancer. 2017;20:111\u201321.","journal-title":"Gastric Cancer"},{"key":"1631_CR13","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/ags3.12060","volume":"2","author":"J Kitayama","year":"2018","unstructured":"Kitayama J, Ishigami H, Yamaguchi H, Sakuma Y, Horie H, Hosoya Y, et al. Treatment of patients with peritoneal metastases from gastric cancer. Ann Gastroenterol Surg. 2018;2:116\u201323.","journal-title":"Ann Gastroenterol Surg"},{"key":"1631_CR14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.5230\/jgc.2020.20.e15","volume":"20","author":"DKA Chia","year":"2020","unstructured":"Chia DKA, So JBY. Recent advances in intra-peritoneal chemotherapy for gastric cancer. J Gastric Cancer. 2020;20:115\u201326.","journal-title":"J Gastric Cancer"},{"key":"1631_CR15","first-page":"26","volume":"1","author":"Y Yonemura","year":"2014","unstructured":"Yonemura Y. A new bidirectional intraperitoneal and systemic induction chemotherapy (BISIC) for the peritoneal metastasis from gastric cancer in neoadjuvant setting. Integr Cancer Sci Ther. 2014;1:26\u20139.","journal-title":"Integr Cancer Sci Ther"},{"key":"1631_CR16","doi-asserted-by":"publisher","first-page":"864647","DOI":"10.3389\/fonc.2022.864647","volume":"12","author":"A Prabhu","year":"2022","unstructured":"Prabhu A, Mishra D, Brandl A, Yonemura Y. Gastric cancer with peritoneal metastasis\u2014a comprehensive review of current intraperitoneal treatment modalities. Front Oncol. 2022;12:864647.","journal-title":"Front Oncol"},{"key":"1631_CR17","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1245\/s10434-011-1620-8","volume":"18","author":"T-S Han","year":"2011","unstructured":"Han T-S, Kong S-H, Lee H-J, Ahn H-S, Hur K, Yu J, et al. Dissemination of free cancer cells from the gastric lumen and from perigastric lymphovascular pedicles during radical gastric cancer surgery. Ann Surg Oncol. 2011;18:2818\u201325.","journal-title":"Ann Surg Oncol"},{"key":"1631_CR18","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.21873\/anticanres.12892","volume":"38","author":"E Virgilio","year":"2018","unstructured":"Virgilio E, Giarnieri E, Giovagnoli MR, Montagnini M, Proietti A, D\u2019Urso R, et al. Gastric cancer cells in peritoneal lavage fluid: a systematic review comparing cytological with molecular detection for diagnosis of peritoneal metastases and prediction of peritoneal recurrences. Anticancer Res. 2018;38:1255\u201362.","journal-title":"Anticancer Res"},{"key":"1631_CR19","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nrc1098","volume":"3","author":"IJ Fidler","year":"2003","unstructured":"Fidler IJ. The pathogenesis of cancer metastasis: the \u201cseed and soil\u201d hypothesis revisited. Nat Rev Cancer. 2003;3:453\u20138.","journal-title":"Nat Rev Cancer"},{"key":"1631_CR20","doi-asserted-by":"publisher","first-page":"6829","DOI":"10.3748\/wjg.v22.i30.6829","volume":"22","author":"M Kanda","year":"2016","unstructured":"Kanda M, Kodera Y. Molecular mechanisms of peritoneal dissemination in gastric cancer. World J Gastroenterol. 2016;22:6829\u201340.","journal-title":"World J Gastroenterol"},{"key":"1631_CR21","doi-asserted-by":"publisher","first-page":"41549","DOI":"10.18632\/oncotarget.14607","volume":"8","author":"W Ge","year":"2017","unstructured":"Ge W, Chen G, Fan X-S. Pathway of peritoneal carcinomatosis maybe hematogenous metastasis rather than peritoneal seeding. Oncotarget. 2017;8:41549\u201354.","journal-title":"Oncotarget"},{"key":"1631_CR22","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/jso.26269","volume":"123","author":"AE Asmar","year":"2021","unstructured":"Asmar AE, Veys I, Larsimont D, Donckier V, Liberale G. Inferior epigastric artery lymph nodes: a pathway for systemic dissemination from peritoneal carcinomatosis? J Surg Oncol. 2021;123:311\u20134.","journal-title":"J Surg Oncol"},{"key":"1631_CR23","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1200\/JCO.21.02745","volume":"40","author":"YX Gwee","year":"2022","unstructured":"Gwee YX, Chia DKA, So J, Ceelen W, Yong WP, Tan P, et al. Integration of genomic biology into therapeutic strategies of gastric cancer peritoneal metastasis. J Clin Oncol. 2022;40:2830.","journal-title":"J Clin Oncol"},{"key":"1631_CR24","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s10120-012-0156-3","volume":"15","author":"Y Kodera","year":"2012","unstructured":"Kodera Y, Ito S, Mochizuki Y, Ohashi N, Tanaka C, Kobayashi D, et al. Long-term follow up of patients who were positive for peritoneal lavage cytology: final report from the CCOG0301 study. Gastric Cancer. 2012;15:335\u20137.","journal-title":"Gastric Cancer"},{"key":"1631_CR25","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1245\/s10434-019-08054-8","volume":"27","author":"T Yamaguchi","year":"2020","unstructured":"Yamaguchi T, Takashima A, Boku N. ASO author reflections: what is the best treatment for gastric cancer with positive peritoneal lavage cytology or localized peritoneum metastasis? Ann Surg Oncol. 2020;27:737\u20138.","journal-title":"Ann Surg Oncol"},{"key":"1631_CR26","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S0002-9610(99)00162-2","volume":"178","author":"E Bando","year":"1999","unstructured":"Bando E, Yonemura Y, Takeshita Y, Taniguchi K, Yasui T, Yoshimitsu Y, et al. Intraoperative lavage for cytological examination in 1,297 patients with gastric carcinoma. Am J Surg. 1999;178:256\u201362.","journal-title":"Am J Surg"},{"key":"1631_CR27","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s10120-017-0749-y","volume":"21","author":"S Jamel","year":"2018","unstructured":"Jamel S, Markar SR, Malietzis G, Acharya A, Athanasiou T, Hanna GB. Prognostic significance of peritoneal lavage cytology in staging gastric cancer: systematic review and meta-analysis. Gastric Cancer. 2018;21:10\u20138.","journal-title":"Gastric Cancer"},{"key":"1631_CR28","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1002\/bjs.4164","volume":"90","author":"F Roviello","year":"2003","unstructured":"Roviello F, Marrelli D, de Manzoni G, Morgagni P, Leo AD, Saragoni L, et al. Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg. 2003;90:1113\u20139.","journal-title":"Br J Surg"},{"key":"1631_CR29","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1067\/msy.2001.114217","volume":"129","author":"S Shimada","year":"2001","unstructured":"Shimada S, Yagi Y, Shiomori K, Honmyo U, Hayashi N, Matsuo A, et al. Characterization of early gastric cancer and proposal of the optimal therapeutic strategy. Surgery. 2001;129:714\u20139.","journal-title":"Surgery"},{"key":"1631_CR30","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1471-2407-13-57","volume":"13","author":"B Huang","year":"2013","unstructured":"Huang B, Sun Z, Wang Z, Lu C, Xing C, Zhao B, et al. Factors associated with peritoneal metastasis in non-serosa-invasive gastric cancer: a retrospective study of a prospectively-collected database. BMC Cancer. 2013;13:57.","journal-title":"BMC Cancer"},{"key":"1631_CR31","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s10120-020-01136-7","volume":"24","author":"Y Iwasaki","year":"2021","unstructured":"Iwasaki Y, Terashima M, Mizusawa J, Katayama H, Nakamura K, Katai H, et al. Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial. Gastric Cancer. 2021;24:492\u2013502.","journal-title":"Gastric Cancer"},{"key":"1631_CR32","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1002\/1097-0142(19900501)65:9<2086::AID-CNCR2820650933>3.0.CO;2-B","volume":"65","author":"Y Esaki","year":"1990","unstructured":"Esaki Y, Hirayama R, Hirokawa K. A comparison of patterns of metastasis in gastric cancer by histologic type and age. Cancer. 1990;65:2086\u201390.","journal-title":"Cancer"},{"key":"1631_CR33","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/jso.23632","volume":"110","author":"JPD Andrade","year":"2014","unstructured":"Andrade JPD, Mezhir JJ. The critical role of peritoneal cytology in the staging of gastric cancer: an evidence-based review. J Surg Oncol. 2014;110:291\u20137.","journal-title":"J Surg Oncol"},{"key":"1631_CR34","doi-asserted-by":"publisher","first-page":"107327482096890","DOI":"10.1177\/1073274820968900","volume":"27","author":"C Zhou","year":"2020","unstructured":"Zhou C, Wang Y, Ji M-H, Tong J, Yang J-J, Xia H. Predicting peritoneal metastasis of gastric cancer patients based on machine learning. Cancer Control. 2020;27:1073274820968900.","journal-title":"Cancer Control"},{"key":"1631_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-022-01331-8","volume":"26","author":"JGC Association","year":"2023","unstructured":"Association JGC. Japanese gastric cancer treatment guidelines 2021 (6th edition). Gastric Cancer. 2023;26:1\u201325.","journal-title":"Gastric Cancer"},{"key":"1631_CR36","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1002\/cac2.12193","volume":"41","author":"F Wang","year":"2021","unstructured":"Wang F, Zhang X, Li Y, Tang L, Qu X, Ying J, et al. The Chinese society of clinical oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun. 2021;41:747\u201395.","journal-title":"Cancer Commun"},{"key":"1631_CR37","doi-asserted-by":"publisher","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","volume":"20","author":"JA Ajani","year":"2022","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2022;20:167\u201392.","journal-title":"J Natl Compr Cancer Netw"},{"key":"1631_CR38","first-page":"256","volume":"40","author":"JS Spratt","year":"1980","unstructured":"Spratt JS, Adcock RA, Muskovin M, Sherrill W, McKeown J. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res. 1980;40:256\u201360.","journal-title":"Cancer Res"},{"key":"1631_CR39","doi-asserted-by":"publisher","first-page":"4538","DOI":"10.1200\/JCO.2020.38.15_suppl.4538","volume":"38","author":"S Cui","year":"2020","unstructured":"Cui S, Liang H, Li Y, Zhou Y, Tao K, Zhou Z, et al. PILGRIM: phase III clinical trial in evaluating the role of hyperthermic intraperitoneal chemotherapy for locally advanced gastric cancer patients after radical gastrectomy with D2 lymphadenectomy (HIPEC-01). J Clin Oncol. 2020;38:4538. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.4538.","journal-title":"J Clin Oncol"},{"key":"1631_CR40","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.21037\/jgo-20-129","volume":"12","author":"MYU Reutovich","year":"2020","unstructured":"Reutovich MYU, Krasko OV, Sukonko OG. Hyperthermic intraperitoneal chemotherapy in prevention of gastric cancer metachronous peritoneal metastases: a systematic review. J Gastrointest Oncol. 2020;12:S5-17.","journal-title":"J Gastrointest Oncol"},{"key":"1631_CR41","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1200\/JCO.18.01688","volume":"37","author":"P-E Bonnot","year":"2019","unstructured":"Bonnot P-E, Piessen G, Kepenekian V, Decullier E, Pocard M, Meunier B, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. J Clin Oncol. 2019;37:2028\u201340.","journal-title":"J Clin Oncol"},{"key":"1631_CR42","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1080\/02656736.2017.1283065","volume":"33","author":"Z-H Ji","year":"2017","unstructured":"Ji Z-H, Peng K-W, Yu Y, Li X-B, Yonemura Y, Liu Y, et al. Current status and future prospects of clinical trials on CRS + HIPEC for gastric cancer peritoneal metastases. Int J Hyperth. 2017;33:562\u201370.","journal-title":"Int J Hyperth"},{"key":"1631_CR43","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s12094-022-03004-5","volume":"25","author":"Z Chen","year":"2022","unstructured":"Chen Z, Ali M, Kai Z, Wang Y, Wang C. HIPEC with CRS versus cytoreductive surgery (CRS) for the gastric cancer metastasis to peritoneum. Clin Transl Oncol\u202f: Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex. 2022;25:1011\u20136.","journal-title":"Clin Transl Oncol : Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex"},{"key":"1631_CR44","first-page":"485","volume":"26","author":"M Cai","year":"2023","unstructured":"Cai M, Li B, Wu L, Ding X, Wang X, Ke B, et al. Prospective phase III randomized controlled clinical study of hyperthermic intraperitoneal chemotherapy (HIPEC) sequentially combined with intraperitoneal and intravenous paclitaxel and oral S-1 for conversion therapy in gastric cancer with peritoneal metastasis (HIPEC-02) - preliminary analysis of single-center data. Chin J Gastrointest Surg. 2023;26:485\u201391.","journal-title":"Chin J Gastrointest Surg"},{"key":"1631_CR45","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1007\/s00464-012-2148-0","volume":"26","author":"W Sola\u00df","year":"2012","unstructured":"Sola\u00df W, Hetzel A, Nadiradze G, Sagynaliev E, Reymond MA. Description of a novel approach for intraperitoneal drug delivery and the related device. Surg Endosc. 2012;26:1849\u201355.","journal-title":"Surg Endosc"},{"key":"1631_CR46","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.3390\/cancers15041125","volume":"15","author":"AD Giorgio","year":"2023","unstructured":"Giorgio AD, Macr\u00ec A, Ferracci F, Robella M, Visaloco M, Manzoni GD, et al. 10 years of pressurized intraperitoneal aerosol chemotherapy (PIPAC): a systematic review and meta-analysis. Cancers. 2023;15:1125.","journal-title":"Cancers"},{"key":"1631_CR47","doi-asserted-by":"publisher","first-page":"167","DOI":"10.5230\/jgc.2011.11.3.167","volume":"11","author":"JM Bae","year":"2011","unstructured":"Bae JM, Yeo KJ, Kim SW, Kim SW, Song SK. Clinical outcomes according to primary treatment in gastric cancer patients with peritoneal seeding. J Gastric Cancer. 2011;11:167\u201372.","journal-title":"J Gastric Cancer"},{"key":"1631_CR48","doi-asserted-by":"publisher","first-page":"266","DOI":"10.5230\/jgc.2014.14.4.266","volume":"14","author":"SW Kim","year":"2014","unstructured":"Kim SW. The result of conversion surgery in gastric cancer patients with peritoneal seeding. J Gastric Cancer. 2014;14:266\u201370.","journal-title":"J Gastric Cancer"},{"key":"1631_CR49","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1245\/s10434-009-0706-z","volume":"16","author":"H Okabe","year":"2009","unstructured":"Okabe H, Ueda S, Obama K, Hosogi H, Sakai Y. Induction chemotherapy with S-1 plus cisplatin followed by surgery for treatment of gastric cancer with peritoneal dissemination. Ann Surg Oncol. 2009;16:3227\u201336.","journal-title":"Ann Surg Oncol"},{"key":"1631_CR50","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s10120-016-0660-y","volume":"20","author":"K Kono","year":"2017","unstructured":"Kono K, Yong W-P, Okayama H, Shabbir A, Momma T, Ohki S, et al. Intraperitoneal chemotherapy for gastric cancer with peritoneal disease: experience from Singapore and Japan. Gastric Cancer. 2017;20:122\u20137.","journal-title":"Gastric Cancer"},{"key":"1631_CR51","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1245\/s10434-020-09388-4","volume":"28","author":"S Saito","year":"2021","unstructured":"Saito S, Yamaguchi H, Ohzawa H, Miyato H, Kanamaru R, Kurashina K, et al. Intraperitoneal administration of paclitaxel combined with S-1 plus oxaliplatin as induction therapy for patients with advanced gastric cancer with peritoneal metastases. Ann Surg Oncol. 2021;28:3863\u201370.","journal-title":"Ann Surg Oncol"},{"key":"1631_CR52","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1245\/s10434-023-14240-6","volume":"31","author":"D Kobayashi","year":"2024","unstructured":"Kobayashi D, Kodera Y, Fukushima R, Morita M, Fushida S, Yamashita N, et al. Phase II study of intraperitoneal administration of paclitaxel combined with S-1 and cisplatin for gastric cancer with peritoneal metastasis. Ann Surg Oncol. 2024;31:735\u201343.","journal-title":"Ann Surg Oncol"},{"key":"1631_CR53","doi-asserted-by":"publisher","first-page":"8597","DOI":"10.1245\/s10434-022-11998-z","volume":"29","author":"DKA Chia","year":"2022","unstructured":"Chia DKA, Sundar R, Kim G, Ang JJ, Lum JHY, Nga ME, et al. Outcomes of a phase II study of Intraperitoneal paclitaxel plus systemic capecitabine and oxaliplatin (XELOX) for gastric cancer with peritoneal metastases. Ann Surg Oncol. 2022;29:8597\u2013605.","journal-title":"Ann Surg Oncol"},{"key":"1631_CR54","doi-asserted-by":"publisher","first-page":"5084","DOI":"10.1245\/s10434-022-11582-5","volume":"29","author":"SH Kang","year":"2022","unstructured":"Kang SH, Min S-H, Kim JW, Lee E, Park SW, Lee S, et al. Safety and efficacy of intraperitoneal paclitaxel plus intravenous fluorouracil, leucovorin, and oxaliplatin (FOLFOX) for gastric cancer with peritoneal metastasis. Ann Surg Oncol. 2022;29:5084\u201391.","journal-title":"Ann Surg Oncol"},{"key":"1631_CR55","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1186\/s12885-021-09027-5","volume":"21","author":"M Shi","year":"2021","unstructured":"Shi M, Yang Z, Lu S, Liu W, Ni Z, Yao X, et al. Oxaliplatin plus S-1 with intraperitoneal paclitaxel for the treatment of Chinese advanced gastric cancer with peritoneal metastases. BMC Cancer. 2021;21:1344.","journal-title":"BMC Cancer"},{"key":"1631_CR56","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.2217\/fon-2021-1414","volume":"18","author":"S Lu","year":"2022","unstructured":"Lu S, Yang Z-Y, Yan C, Liu W-T, Ni Z-T, Yao X-X, et al. A phase III trial of neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis. Futur Oncol. 2022;18:1175\u201383.","journal-title":"Futur Oncol"},{"key":"1631_CR57","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.2217\/fon-2022-0738","volume":"19","author":"H Yuan","year":"2023","unstructured":"Yuan H, Lu S, Shi M, Yang Z, Liu W, Ni Z, et al. Sintilimab combined neoadjuvant intraperitoneal and systemic chemotherapy in gastric cancer with peritoneal metastasis. Futur Oncol. 2023;19:2517\u201323.","journal-title":"Futur Oncol"},{"key":"1631_CR58","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/978-1-4613-1247-5_4","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Sugarbaker PH. Peritoneal carcinomatosis: principles of management. Cancer Treat Res. 1996;82:53\u201363.","journal-title":"Cancer Treat Res"},{"key":"1631_CR59","doi-asserted-by":"publisher","first-page":"H26","DOI":"10.1152\/ajpheart.1985.248.1.H26","volume":"248","author":"MF Flessner","year":"1985","unstructured":"Flessner MF, Fenstermacher JD, Blasberg RG, Dedrick RL. Peritoneal absorption of macromolecules studied by quantitative autoradiography. Am J Physiol-Hear Circ Physiol. 1985;248:H26-32.","journal-title":"Am J Physiol-Hear Circ Physiol"},{"key":"1631_CR60","first-page":"1","volume":"12","author":"RL Dedrick","year":"1985","unstructured":"Dedrick RL. Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol. 1985;12:1\u20136.","journal-title":"Semin Oncol"},{"key":"1631_CR61","first-page":"637","volume":"27","author":"N Ohashi","year":"2005","unstructured":"Ohashi N, Kodera Y, Nakanishi H, Yokoyama H, Fujiwara M, Koike M, et al. Efficacy of intraperitoneal chemotherapy with paclitaxel targeting peritoneal micrometastasis as revealed by GFP-tagged human gastric cancer cell lines in nude mice. Int J Oncol. 2005;27:637\u201344.","journal-title":"Int J Oncol"},{"key":"1631_CR62","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s00280-002-0439-1","volume":"49","author":"P Marchettini","year":"2002","unstructured":"Marchettini P, Stuart AO, Mohamed F, Yoo D, Sugarbaker PH. Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model. Cancer Chemother Pharmacol. 2002;49:499\u2013503.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1631_CR63","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1159\/000209277","volume":"76","author":"H Ishigami","year":"2009","unstructured":"Ishigami H, Kitayama J, Otani K, Kamei T, Soma D, Miyato H, et al. Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer. Oncology. 2009;76:311\u20134.","journal-title":"Oncology"},{"key":"1631_CR64","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1517\/14656566.2014.879571","volume":"15","author":"Y Yonemura","year":"2014","unstructured":"Yonemura Y, Canbay E, Endou Y, Ishibashi H, Mizumoto A, Miura M, et al. Peritoneal cancer treatment. Expert Opin Pharmacother. 2014;15:623\u201336.","journal-title":"Expert Opin Pharmacother"},{"key":"1631_CR65","doi-asserted-by":"publisher","first-page":"418","DOI":"10.5230\/jgc.2021.21.e38","volume":"21","author":"D-W Kim","year":"2021","unstructured":"Kim D-W, Seo WJ, Youn SI, Jee YS, Jang Y-J, Kim J-H, et al. Intraperitoneal paclitaxel combined with S-1 plus oxaliplatin for advanced gastric cancer with peritoneal metastasis: a phase I study. J Gastric Cancer. 2021;21:418.","journal-title":"J Gastric Cancer"},{"key":"1631_CR66","doi-asserted-by":"publisher","first-page":"e53651","DOI":"10.1371\/journal.pone.0053651","volume":"8","author":"Z Pan","year":"2013","unstructured":"Pan Z, Pang L, Ding B, Yan C, Zhang H, Du L, et al. Gastric cancer staging with dual energy spectral CT imaging. PLoS ONE. 2013;8:e53651.","journal-title":"PLoS ONE"},{"key":"1631_CR67","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10120-011-0069-6","volume":"15","author":"R Seevaratnam","year":"2012","unstructured":"Seevaratnam R, Cardoso R, Mcgregor C, Lourenco L, Mahar A, Sutradhar R, et al. How useful is preoperative imaging for tumor, node, metastasis (TNM) staging of gastric cancer? Meta-Anal Gastric Cancer. 2012;15:3\u201318.","journal-title":"Meta-Anal Gastric Cancer"},{"key":"1631_CR68","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/BF02984657","volume":"20","author":"A Yamada","year":"2006","unstructured":"Yamada A, Oguchi K, Fukushima M, Imai Y, Kadoya M. Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in gastric carcinoma: relation to histological subtypes, depth of tumor invasion, and glucose transporter-1 expression. Ann Nucl Med. 2006;20:597\u2013604.","journal-title":"Ann Nucl Med"},{"key":"1631_CR69","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1093\/annonc\/mdz001","volume":"30","author":"D Dong","year":"2019","unstructured":"Dong D, Tang L, Li Z-Y, Fang M-J, Gao J-B, Shan X-H, et al. Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer. Ann Oncol. 2019;30:431\u20138.","journal-title":"Ann Oncol"},{"key":"1631_CR70","doi-asserted-by":"publisher","first-page":"659981","DOI":"10.3389\/fonc.2021.659981","volume":"11","author":"Y Chen","year":"2021","unstructured":"Chen Y, Xi W, Yao W, Wang L, Xu Z, Wels M, et al. Dual-energy computed tomography-based radiomics to predict peritoneal metastasis in gastric cancer. Front Oncol. 2021;11:659981.","journal-title":"Front Oncol"},{"key":"1631_CR71","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1097\/MNM.0b013e32833823ac","volume":"31","author":"H Alakus","year":"2010","unstructured":"Alakus H, Batur M, Schmidt M, Drebber U, Baldus SE, Vallb\u00f6hmer D, et al. Variable 18F-fluorodeoxyglucose uptake in gastric cancer is associated with different levels of GLUT-1 expression. Nucl Med Commun. 2010;31:532\u20138.","journal-title":"Nucl Med Commun"},{"key":"1631_CR72","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1007\/s00259-022-05799-5","volume":"49","author":"R Lin","year":"2022","unstructured":"Lin R, Lin Z, Chen Z, Zheng S, Zhang J, Zang J, et al. [68Ga]Ga-DOTA-FAPI-04 PET\/CT in the evaluation of gastric cancer: comparison with [18F]FDG PET\/CT. Eur J Nucl Med Mol Imaging. 2022;49:2960\u201371.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1631_CR73","doi-asserted-by":"publisher","first-page":"6351330","DOI":"10.1155\/2023\/6351330","volume":"2023","author":"T Du","year":"2023","unstructured":"Du T, Zhang S, Cui X-M, Hu R-H, Wang H-Y, Jiang J-J, et al. Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F]FDG PET\/MRI in the preoperative diagnosis of gastric cancer. Can J Gastroenterol Hepatol. 2023;2023:6351330.","journal-title":"Can J Gastroenterol Hepatol"},{"key":"1631_CR74","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1007\/s00259-020-05146-6","volume":"48","author":"L Zhao","year":"2021","unstructured":"Zhao L, Pang Y, Luo Z, Fu K, Yang T, Zhao L, et al. Role of [68Ga]Ga-DOTA-FAPI-04 PET\/CT in the evaluation of peritoneal carcinomatosis and comparison with [18F]-FDG PET\/CT. Eur J Nucl Med Mol Imaging. 2021;48:1944\u201355.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1631_CR75","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ygyno.2016.04.018","volume":"142","author":"J Fehniger","year":"2016","unstructured":"Fehniger J, Thomas S, Lengyel E, Liao C, Tenney M, Oto A, et al. A prospective study evaluating diffusion weighted magnetic resonance imaging (DW-MRI) in the detection of peritoneal carcinomatosis in suspected gynecologic malignancies. Gynecol Oncol. 2016;142:169\u201375.","journal-title":"Gynecol Oncol"},{"key":"1631_CR76","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1053\/j.seminoncol.2004.04.014","volume":"31","author":"EK Abdalla","year":"2004","unstructured":"Abdalla EK, Pisters PWT. Staging and preoperative evaluation of upper gastrointestinal malignancies. Semin Oncol. 2004;31:513\u201329.","journal-title":"Semin Oncol"},{"key":"1631_CR77","first-page":"287","volume":"30","author":"N Machairas","year":"2017","unstructured":"Machairas N, Charalampoudis P, Molmenti EP, Kykalos S, Tsaparas P, Stamopoulos P, et al. The value of staging laparoscopy in gastric cancer. Ann Gastroenterol. 2017;30:287\u201394.","journal-title":"Ann Gastroenterol"},{"key":"1631_CR78","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.ejso.2016.06.401","volume":"42","author":"RF Ramos","year":"2016","unstructured":"Ramos RF, Scalon FM, Scalon MM, Dias DI. Staging laparoscopy in gastric cancer to detect peritoneal metastases: a systematic review and meta-analysis. Eur J Surg Oncol (EJSO). 2016;42:1315\u201321.","journal-title":"Eur J Surg Oncol (EJSO)"},{"key":"1631_CR79","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.3390\/cancers15133425","volume":"15","author":"CA Schena","year":"2023","unstructured":"Schena CA, Laterza V, Sio DD, Quero G, Fiorillo C, Gunawardena G, et al. The role of staging laparoscopy for gastric cancer patients: current evidence and future perspectives. Cancers. 2023;15:3425.","journal-title":"Cancers"},{"key":"1631_CR80","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/ags3.12283","volume":"3","author":"T Fukagawa","year":"2019","unstructured":"Fukagawa T. Role of staging laparoscopy for gastric cancer patients. Ann Gastroenterol Surg. 2019;3:496\u2013505.","journal-title":"Ann Gastroenterol Surg"},{"key":"1631_CR81","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00464-017-5673-z","volume":"32","author":"T Irino","year":"2018","unstructured":"Irino T, Sano T, Hiki N, Ohashi M, Nunobe S, Kumagai K, et al. Diagnostic staging laparoscopy in gastric cancer: a prospective cohort at a cancer institute in Japan. Surg Endosc. 2018;32:268\u201375.","journal-title":"Surg Endosc"},{"key":"1631_CR82","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1245\/ASO.2005.03.065","volume":"12","author":"D Bentrem","year":"2005","unstructured":"Bentrem D, Wilton A, Mazumdar M, Brennan M, Coit D. The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection. Ann Surg Oncol. 2005;12:347\u201353.","journal-title":"Ann Surg Oncol"},{"key":"1631_CR83","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Sugarbaker PH. Peritoneal carcinomatosis: principles of management. Cancer Treat Res. 1996;82:359\u201374.","journal-title":"Cancer Treat Res"},{"key":"1631_CR84","doi-asserted-by":"publisher","first-page":"e215340","DOI":"10.1001\/jamasurg.2021.5340","volume":"156","author":"EC Gertsen","year":"2021","unstructured":"Gertsen EC, Brenkman HJF, van Hillegersberg R, van Sandick JW, van Henegouwen MI B, Gisbertz SS, et al. 18F-fludeoxyglucose-positron emission tomography\/computed tomography and laparoscopy for staging of locally advanced gastric cancer: a multicenter prospective dutch cohort study (PLASTIC). JAMA Surg. 2021;156:e215340.","journal-title":"JAMA Surg"},{"key":"1631_CR85","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.1002\/cncr.28204","volume":"119","author":"H Yamaguchi","year":"2013","unstructured":"Yamaguchi H, Kitayama J, Ishigami H, Emoto S, Yamashita H, Watanabe T. A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis. Cancer. 2013;119:3354\u20138.","journal-title":"Cancer"},{"key":"1631_CR86","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/annonc\/mdp260","volume":"21","author":"H Ishigami","year":"2010","unstructured":"Ishigami H, Kitayama J, Kaisaki S, Hidemura A, Kato M, Otani K, et al. Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol. 2010;21:67\u201370.","journal-title":"Ann Oncol"},{"key":"1631_CR87","first-page":"126","volume":"3","author":"Z Li","year":"2015","unstructured":"Li Z, Ji J. Application of laparoscopy in the diagnosis and treatment of gastric cancer. Ann Transl Med. 2015;3:126.","journal-title":"Ann Transl Med"},{"key":"1631_CR88","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1245\/s10434-021-10922-1","volume":"29","author":"F Shariff","year":"2022","unstructured":"Shariff F, Bogach J, Guidolin K, Nadler A. Malignant bowel obstruction management over time: are we doing anything new? a current narrative review. Ann Surg Oncol. 2022;29:1995\u20132005.","journal-title":"Ann Surg Oncol"},{"key":"1631_CR89","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4236\/jct.2013.49A1002","volume":"04","author":"S Fushida","year":"2013","unstructured":"Fushida S, Oyama K, Kinoshita J, Tsukada T, Okamoto K, Tajima H, et al. Intraperitoneal chemotherapy as a multimodal treatment for gastric cancer patients with peritoneal metastasis. J Cancer Ther. 2013;04:6\u201315.","journal-title":"J Cancer Ther"},{"key":"1631_CR90","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1515\/pp-2017-0002","volume":"2","author":"J Kitayama","year":"2017","unstructured":"Kitayama J, Ishigami H, Yamaguchi H, Yamada J, Soma D, Miyato H, et al. Optimal drug delivery for intraperitoneal paclitaxel (PTX) in murine model. Pleura Peritoneum. 2017;2:95\u2013102.","journal-title":"Pleura Peritoneum"},{"key":"1631_CR91","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1002\/jso.23928","volume":"111","author":"Y Peng","year":"2015","unstructured":"Peng Y, Imano M, Itoh T, Satoh T, Chiba Y, Imamoto H, et al. A phase II trial of perioperative chemotherapy involving a single intraperitoneal administration of paclitaxel followed by sequential S-1 plus intravenous paclitaxel for serosa-positive gastric cancer. J Surg Oncol. 2015;111:1041\u20136.","journal-title":"J Surg Oncol"},{"key":"1631_CR92","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1007\/s11605-012-2059-3","volume":"16","author":"M Imano","year":"2012","unstructured":"Imano M, Yasuda A, Itoh T, Satou T, Peng Y-F, Kato H, et al. Phase II study of single intraperitoneal chemotherapy followed by systemic chemotherapy for gastric cancer with peritoneal metastasis. J Gastrointest Surg. 2012;16:2190\u20136.","journal-title":"J Gastrointest Surg"},{"key":"1631_CR93","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/jso.22057","volume":"105","author":"Y Fujiwara","year":"2012","unstructured":"Fujiwara Y, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Kurokawa Y, et al. Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination. J Surg Oncol. 2012;105:38\u201342.","journal-title":"J Surg Oncol"},{"key":"1631_CR94","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1159\/000323272","volume":"79","author":"H Ishigami","year":"2011","unstructured":"Ishigami H, Kitayama J, Kaisaki S, Yamaguchi H, Yamashita H, Emoto S, et al. Phase I study of biweekly intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel for gastric cancer with peritoneal metastasis. Oncology. 2011;79:269\u201372.","journal-title":"Oncology"},{"key":"1631_CR95","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.21037\/jgo-2020-04","volume":"12","author":"A Brandl","year":"2020","unstructured":"Brandl A, Prabhu A. Intraperitoneal chemotherapy in the treatment of gastric cancer peritoneal metastases: an overview of common therapeutic regimens. J Gastrointest Oncol. 2020;12:S32-44.","journal-title":"J Gastrointest Oncol"},{"key":"1631_CR96","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1245\/s10434-022-12837-x","volume":"30","author":"A Mariani","year":"2023","unstructured":"Mariani A, Zaanan A, Glehen O, Karoui M. Outcomes of a phase II study of intraperitoneal paclitaxel plus systemic capecitabine and oxaliplatin (XELOX) for gastric cancer with peritoneal metastases. Ann Surg Oncol. 2023;30:816\u20137.","journal-title":"Ann Surg Oncol"},{"key":"1631_CR97","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.1002\/cam4.5277","volume":"12","author":"L Tu","year":"2023","unstructured":"Tu L, Zhang W, Ni L, Xu Z, Yang K, Gou H, et al. Study of SOX combined with intraperitoneal high-dose paclitaxel in gastric cancer with synchronous peritoneal metastasis: a phase II single-arm clinical trial. Cancer Med. 2023;12:4161\u20139.","journal-title":"Cancer Med"},{"key":"1631_CR98","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s00280-013-2122-0","volume":"71","author":"S Fushida","year":"2013","unstructured":"Society for the Study of Peritoneal Carcinomatosis in Gastric Cancer, Fushida S, Kinoshita J, Kaji M, Hirono Y, Goda F, et al. Phase I\/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol. 2013;71:1265\u201372.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1631_CR99","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3390\/cancers12010116","volume":"12","author":"Y Yonemura","year":"2020","unstructured":"Yonemura Y, Prabhu A, Sako S, Ishibashi H, Mizumoto A, Takao N, et al. Long term survival after cytoreductive surgery combined with perioperative chemotherapy in gastric cancer patients with peritoneal metastasis. Cancers. 2020;12:116.","journal-title":"Cancers"},{"key":"1631_CR100","doi-asserted-by":"publisher","first-page":"720858","DOI":"10.1155\/2013\/720858","volume":"2013","author":"LD Smet","year":"2013","unstructured":"Smet LD, Ceelen W, Remon JP, Vervaet C. Optimization of drug delivery systems for intraperitoneal therapy to extend the residence time of the chemotherapeutic agent. Sci World J. 2013;2013:720858.","journal-title":"Sci World J"},{"key":"1631_CR101","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/0090-8258(78)90010-0","volume":"6","author":"N Rosenshein","year":"1978","unstructured":"Rosenshein N, Blake D, McIntyre PA, Parmley T, Natarajan TK, Dvornicky J, et al. The effect of volume on the distribution of substances instilled into the peritoneal cavity. Gynecol Oncol. 1978;6:106\u201310.","journal-title":"Gynecol Oncol"},{"key":"1631_CR102","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.soc.2018.02.003","volume":"27","author":"N Lagast","year":"2018","unstructured":"Lagast N, Carlier C, Ceelen WP. Pharmacokinetics and tissue transport of intraperitoneal chemotherapy. Surg Oncol Clin North Am. 2018;27:477\u201394.","journal-title":"Surg Oncol Clin North Am"},{"key":"1631_CR103","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1515\/pp-2017-0003","volume":"2","author":"KV der Speeten","year":"2017","unstructured":"der Speeten KV, Lemoine L, Sugarbaker P. Overview of the optimal perioperative intraperitoneal chemotherapy regimens used in current clinical practice. Pleura Peritoneum. 2017;2:63\u201372.","journal-title":"Pleura Peritoneum"},{"key":"1631_CR104","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/0090-8258(86)90006-5","volume":"24","author":"CD Runowicz","year":"1986","unstructured":"Runowicz CD, Dottino PR, Shafir MK, Mark MA, Cohen CJ. Catheter complications associated with intraperitoneal chemotherapy. Gynecol Oncol. 1986;24:41\u201350.","journal-title":"Gynecol Oncol"},{"key":"1631_CR105","doi-asserted-by":"publisher","first-page":"497","DOI":"10.21147\/j.issn.1000-9604.2020.04.07","volume":"32","author":"Z Yang","year":"2020","unstructured":"Yang Z, Li C, Liu W, Zheng Y, Zhu Z, Hua Z, et al. Complications and risk factors for complications of implanted subcutaneous ports for intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis. Chin J Cancer Res. 2020;32:497\u2013507.","journal-title":"Chin J Cancer Res"},{"key":"1631_CR106","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1093\/jjco\/hys129","volume":"42","author":"S Emoto","year":"2012","unstructured":"Emoto S, Ishigami H, Hidemura A, Yamaguchi H, Yamashita H, Kitayama J, et al. Complications and management of an implanted intraperitoneal access port system for intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis. Jpn J Clin Oncol. 2012;42:1013\u20139.","journal-title":"Jpn J Clin Oncol"},{"key":"1631_CR107","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/0090-8258(91)90266-8","volume":"41","author":"SA Davidson","year":"1991","unstructured":"Davidson SA, Rubin SC, Markman M, Jones WB, Hakes TB, Reichman B, et al. Intraperitoneal chemotherapy: analysis of complications with an implanted subcutaneous port and catheter system. Gynecol Oncol. 1991;41:101\u20136.","journal-title":"Gynecol Oncol"},{"key":"1631_CR108","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s10120-015-0575-z","volume":"19","author":"K Yoshida","year":"2016","unstructured":"Yoshida K, Yamaguchi K, Okumura N, Tanahashi T, Kodera Y. Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer. 2016;19:329\u201338.","journal-title":"Gastric Cancer"},{"key":"1631_CR109","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s10120-016-0684-3","volume":"20","author":"H Ishigami","year":"2017","unstructured":"Ishigami H, Yamaguchi H, Yamashita H, Asakage M, Kitayama J. Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings. Gastric Cancer. 2017;20:128\u201334.","journal-title":"Gastric Cancer"},{"key":"1631_CR110","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s00423-021-02410-7","volume":"407","author":"M Shinkai","year":"2022","unstructured":"Shinkai M, Imano M, Hiraki Y, Momose K, Kato H, Shiraishi O, et al. Efficacy of conversion surgery after a single intraperitoneal administration of paclitaxel and systemic chemotherapy for gastric cancer with peritoneal metastasis. Langenbeck\u2019s Arch Surg. 2022;407:975\u201383.","journal-title":"Langenbeck\u2019s Arch Surg"},{"key":"1631_CR111","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.21037\/jgo-21-431","volume":"13","author":"M Shinkai","year":"2022","unstructured":"Shinkai M, Imano M. The clinical effect of conversion surgery for advanced gastric cancer patients with peritoneal metastasis. J Gastrointest Oncol. 2022;13:2169.","journal-title":"J Gastrointest Oncol"},{"key":"1631_CR112","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/ags3.12515","volume":"6","author":"K Yoshida","year":"2022","unstructured":"Yoshida K, Yasufuku I, Terashima M, Rha SY, Bae JM, Li G, et al. International retrospective cohort study of conversion therapy for stage IV gastric cancer 1 (CONVO-GC-1). Ann Gastroenterol Surg. 2022;6:227\u201340.","journal-title":"Ann Gastroenterol Surg"},{"key":"1631_CR113","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/ags3.12343","volume":"4","author":"K Yamamoto","year":"2020","unstructured":"Yamamoto K, Omori T, Hara H, Shinno N, Sugimura K, Miyata H, et al. Minimally invasive surgery is feasible after preoperative chemotherapy for stage IV gastric cancer. Ann Gastroenterol Surg. 2020;4:396\u2013404.","journal-title":"Ann Gastroenterol Surg"},{"key":"1631_CR114","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1186\/s12893-022-01874-8","volume":"22","author":"Y Kano","year":"2022","unstructured":"Kano Y, Ichikawa H, Hanyu T, Muneoka Y, Ishikawa T, Aizawa M, et al. Conversion surgery for stage IV gastric cancer: a multicenter retrospective study. BMC Surg. 2022;22:428.","journal-title":"BMC Surg"},{"key":"1631_CR115","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1470-2045(21)00297-7","volume":"22","author":"X Zhang","year":"2021","unstructured":"Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021;22:1081\u201392.","journal-title":"Lancet Oncol"},{"key":"1631_CR116","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.21037\/atm-20-7802","volume":"8","author":"Y Zheng","year":"2020","unstructured":"Zheng Y, Wang Z, Yan C, Yan M, Hou Z, Zheng R, et al. Protocol for a randomized controlled trial of perioperative S-1 plus oxaliplatin combined with apatinib and camrelizumab in patients with resectable, locally advanced gastric or gastroesophageal junction adenocarcinoma. Ann Transl Med. 2020;8:1684.","journal-title":"Ann Transl Med"},{"key":"1631_CR117","doi-asserted-by":"publisher","first-page":"270","DOI":"10.4143\/crt.2014.46.3.270","volume":"46","author":"OK Kwon","year":"2014","unstructured":"Kwon OK, Chung HY, Yu W. Early postoperative intraperitoneal chemotherapy for macroscopically serosa-invading gastric cancer patients. Cancer Res Treat. 2014;46:270\u20139.","journal-title":"Cancer Res Treat"},{"key":"1631_CR118","doi-asserted-by":"publisher","first-page":"50","DOI":"10.5230\/jgc.2020.20.e6","volume":"20","author":"D-W Kim","year":"2020","unstructured":"Kim D-W, Jee YS, Kim CH, Kim J-J, Park S, Choi SI, et al. Multicenter retrospective analysis of intraperitoneal paclitaxel and systemic chemotherapy for advanced gastric cancer with peritoneal metastasis. J Gastric Cancer. 2020;20:50\u20139.","journal-title":"J Gastric Cancer"},{"key":"1631_CR119","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s10585-017-9856-8","volume":"34","author":"O Kube\u010dek","year":"2017","unstructured":"Kube\u010dek O, Laco J, \u0160pa\u010dek J, Petera J, Kopeck\u00fd J, Kube\u010dkov\u00e1 A, et al. The pathogenesis, diagnosis, and management of metastatic tumors to the ovary: a comprehensive review. Clin Exp Metastasis. 2017;34:295\u2013307.","journal-title":"Clin Exp Metastasis"},{"key":"1631_CR120","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.suronc.2017.09.001","volume":"26","author":"A Agnes","year":"2017","unstructured":"Agnes A, Biondi A, Ricci R, Gallotta V, D\u2019Ugo D, Persiani R. Krukenberg tumors: seed, route and soil. Surg Oncol. 2017;26:438\u201345.","journal-title":"Surg Oncol"},{"key":"1631_CR121","doi-asserted-by":"publisher","first-page":"14486","DOI":"10.1002\/jcb.28708","volume":"120","author":"C Zhang","year":"2019","unstructured":"Zhang C, Hou W, Huang J, Yin S, Wang P, Zhang Z, et al. Effects of metastasectomy and other factors on survival of patients with ovarian metastases from gastric cancer: a systematic review and meta-analysis. J Cell Biochem. 2019;120:14486\u201398.","journal-title":"J Cell Biochem"},{"key":"1631_CR122","doi-asserted-by":"publisher","first-page":"82558","DOI":"10.18632\/oncotarget.19759","volume":"8","author":"P Yu","year":"2017","unstructured":"Yu P, Huang L, Cheng G, Yang L, Dai G, Ying J, et al. Treatment strategy and prognostic factors for Krukenberg tumors of gastric origin: report of a 10-year single-center experience from China. Oncotarget. 2017;8:82558\u201370.","journal-title":"Oncotarget"},{"key":"1631_CR123","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1136\/ijgc-00009577-200807000-00034","volume":"18","author":"J Wang","year":"2008","unstructured":"Wang J, Shi Y-K, Wu L-Y, Wang J-W, Yang S, Yang J-L, et al. Prognostic factors for ovarian metastases from primary gastric cancer. Int J Gynecol Cancer. 2008;18:825.","journal-title":"Int J Gynecol Cancer"},{"key":"1631_CR124","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1068-607X(98)00047-X","volume":"5","author":"F McGill","year":"1998","unstructured":"McGill F, Ritter DB, Rickard C, Kaleya RN, Wadler S, Greston WM. Management of Krukenberg tumors: an 11-year experience and review of the literature. Prim Care Updat OBGYNS. 1998;5:157\u20138.","journal-title":"Prim Care Updat OBGYNS"},{"key":"1631_CR125","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1200\/JCO.2011.36.5908","volume":"29","author":"M Sasako","year":"2011","unstructured":"Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387\u201393.","journal-title":"J Clin Oncol"},{"key":"1631_CR126","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(14)70473-5","volume":"15","author":"SH Noh","year":"2014","unstructured":"Noh SH, Park SR, Yang H-K, Chung HC, Chung I-J, Kim S-W, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:1389\u201396.","journal-title":"Lancet Oncol"},{"key":"1631_CR127","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1200\/JCO.18.01138","volume":"37","author":"K Yoshida","year":"2019","unstructured":"Yoshida K, Kodera Y, Kochi M, Ichikawa W, Kakeji Y, Sano T, et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol. 2019;37:1296\u2013304.","journal-title":"J Clin Oncol."},{"key":"1631_CR128","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s40792-020-00849-2","volume":"6","author":"K Miyatani","year":"2020","unstructured":"Miyatani K, Miyauchi W, Kono Y, Shishido Y, Watanabe J, Hanaki T, et al. Successful treatment of peritoneal recurrence after gastric cancer surgery with intravenous and intraperitoneal paclitaxel combined with S-1 chemotherapy: a case report. Surg Case Rep. 2020;6:88.","journal-title":"Surg Case Rep"},{"key":"1631_CR129","doi-asserted-by":"publisher","first-page":"15062","DOI":"10.1200\/jco.2007.25.18_suppl.15062","volume":"25","author":"R Xu","year":"2007","unstructured":"Xu R, Han B, Shi Y, Xiong J, Li Y, Wang F, et al. Phase II clinical trial of XELOX as first line treatment for patients with unresectable or metastatic gastric cancer. J Clin Oncol. 2007;25:15062.","journal-title":"J Clin Oncol"},{"key":"1631_CR130","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s10120-020-01101-4","volume":"24","author":"K-W Lee","year":"2021","unstructured":"Lee K-W, Chung I-J, Ryu M-H, Park YI, Nam B-H, Oh H-S, et al. Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial). Gastric Cancer. 2021;24:156\u201367.","journal-title":"Gastric Cancer"},{"key":"1631_CR131","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27\u201340.","journal-title":"Lancet"},{"key":"1631_CR132","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.annonc.2023.01.006","volume":"34","author":"SY Rha","year":"2023","unstructured":"Rha SY, Wyrwicz LS, Weber PEY, Bai Y, Ryu MH, Lee J, et al. VP1-2023: pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G\/GEJ) cancer: phase III KEYNOTE-859 study. Ann Oncol. 2023;34:319\u201320.","journal-title":"Ann Oncol"},{"key":"1631_CR133","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"Y-J Bang","year":"2010","unstructured":"Bang Y-J, Cutsem EV, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687\u201397.","journal-title":"Lancet"},{"key":"1631_CR134","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang Y-J, Enzinger P, Ilson D, Shah MA, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401:1655\u201368.","journal-title":"Lancet"},{"key":"1631_CR135","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA, Bang Y-J, Enzinger P, Ilson D, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29:2133\u201341.","journal-title":"Nat Med"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-025-01631-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-025-01631-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-025-01631-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T08:54:22Z","timestamp":1757235262000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-025-01631-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":135,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1631"],"URL":"https:\/\/doi.org\/10.1007\/s10120-025-01631-9","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,14]]},"assertion":[{"value":"25 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been updated to amend a typo in the author group.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}